Tăng mức độ của thụ thể hòa tan cho các sản phẩm cuối glycation tiên tiến liên quan đến bệnh teo cơ: một nghiên cứu quan sát

Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998–5004. https://doi.org/10.1016/S0021-9258(18)42138-2. Schmidt AM. Soluble RAGEs - prospects for treating & tracking metabolic and inflammatory disease. Vasc Pharmacol. 2015;72:1–8. https://doi.org/10.1016/j.vph.2015.06.011. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4(9):1025–31. https://doi.org/10.1038/2012. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106(22):2827–35. https://doi.org/10.1161/01.CIR.0000039325.03698.36. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007;48(2):858–65. https://doi.org/10.1167/iovs.06-0495. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011;60(9):2379–85. https://doi.org/10.2337/db11-0291. Butcher L, Carnicero JA, Gomez Cabrero D, Dartigues JF, Pérès K, Garcia-Garcia FJ, et al. Increased levels of soluble receptor for advanced glycation end-products (RAGE) are associated with a higher risk of mortality in frail older adults. Age Ageing. 2019;48(5):696–702. https://doi.org/10.1093/ageing/afz073. Reichert S, Triebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A, et al. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9. https://doi.org/10.1016/j.atherosclerosis.2017.08.015. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300–7 e2. Mori H, Kuroda A, Ishizu M, Ohishi M, Takashi Y, Otsuka Y, et al. Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. J Diabetes Investig. 2019;10(5):1332–40. https://doi.org/10.1111/jdi.13014. Eguchi Y, Toyoguchi T, Inage K, Fujimoto K, Orita S, Suzuki M, et al. Advanced glycation end products are associated with sarcopenia in older women: aging marker dynamics. J Women Aging. 2019;33(3):1–13. https://doi.org/10.1080/08952841.2019.1697161. Piñero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron M, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database. 2015;2015(0). https://doi.org/10.1093/database/bav028. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14(1):7. https://doi.org/10.1186/1471-2105-14-7. Riuzzi F, Sorci G, Sagheddu R, Chiappalupi S, Salvadori L, Donato R. RAGE in the pathophysiology of skeletal muscle. J Cachexia Sarcopenia Muscle. 2018;9(7):1213–34. https://doi.org/10.1002/jcsm.12350. Mori H, Kuroda A, Araki M, Suzuki R, Taniguchi S, Tamaki M, et al. Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. J Diabetes Investig. 2017;8(3):377–82. https://doi.org/10.1111/jdi.12582. Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, et al. Skin advanced glycation end product accumulation and muscle strength among adult men. Eur J Appl Physiol. 2011;111(7):1545–52. https://doi.org/10.1007/s00421-010-1779-x. Fokkens BT, Smit AJ. Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes. Glycoconj J. 2016;33(4):527–35. https://doi.org/10.1007/s10719-016-9683-1. Chiu CY, Yang RS, Sheu ML, Chan DC, Yang TH, Tsai KS, et al. Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway. J Pathol. 2016;238(3):470–82. https://doi.org/10.1002/path.4674. Howard AC, McNeil AK, Xiong F, Xiong WC, McNeil PL. A novel cellular defect in diabetes: membrane repair failure. Diabetes. 2011;60(11):3034–43. https://doi.org/10.2337/db11-0851. Egawa T, Ohno Y, Yokoyama S, Goto A, Ito R, Hayashi T, et al. The effect of advanced glycation end products on cellular signaling molecules in skeletal muscle. J Phys Fitness and Sports Med. 2018;7(4):229–38. https://doi.org/10.7600/jpfsm.7.229. Chen JH, Lin X, Bu C, Zhang X. Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutr Metab. 2018;15(1):72. https://doi.org/10.1186/s12986-018-0306-7. Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Applied Physiol (Bethesda, Md : 1985). 2007;103(6):2068–76. Snow LM, Fugere NA, Thompson LV. Advanced glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging. J Gerontol A Biol Sci Med Sci. 2007;62(11):1204–10. https://doi.org/10.1093/gerona/62.11.1204. Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol. 2004;24(11):4880–94. https://doi.org/10.1128/MCB.24.11.4880-4894.2004. Molin CJ, Westerberg E, Punga AR. Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients. Sci Rep. 2017;7(1):39716. https://doi.org/10.1038/srep39716. Angelopoulou E, Paudel YN, Piperi C. Unraveling the role of receptor for advanced glycation end products (RAGE) and its ligands in myasthenia gravis. ACS Chem Neurosci. 2020;11(5):663–73. https://doi.org/10.1021/acschemneuro.9b00678. Haslbeck KM, Friess U, Schleicher ED, Bierhaus A, Nawroth PP, Kirchner A, et al. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy. Acta Neuropathol. 2005;110(3):247–54. https://doi.org/10.1007/s00401-005-1043-3. Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004;50(5):1586–94. https://doi.org/10.1002/art.20220. Kim TN, Park MS, Lee EJ, Chung HS, Yoo HJ, Kang HJ, et al. The association of low muscle mass with soluble receptor for advanced glycation end products (sRAGE): The Korean Sarcopenic Obesity Study (KSOS). Diabetes Metab Res Rev. 2018;34(3). Gomez-Cabrero D, Walter S, Abugessaisa I, Miñambres-Herraiz R, Palomares LB, Butcher L, et al. A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. GeroScience. 2021;43(3):1317–29. https://doi.org/10.1007/s11357-021-00334-0. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13(17):1971–8. https://doi.org/10.2174/092986706777585013. Erusalimsky JD. The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol. 2021;42:101958. https://doi.org/10.1016/j.redox.2021.101958. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22(10):3716–27. https://doi.org/10.1096/fj.08-109033. Pertynska-Marczewska M, Merhi Z. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women. Reprod Sci (Thousand Oaks, Calif). 2015;22(7):774–82. Merhi Z. Advanced glycation end-products: pathway of potentially significant pathophysiological and therapeutic relevance for metabolic syndrome in menopausal women. J Clin Endocrinol Metab. 2014;99(4):1146–8. https://doi.org/10.1210/jc.2013-4465. Ebert H, Lacruz ME, Kluttig A, Simm A, Greiser KH, Tiller D, et al. Advanced glycation end products and their ratio to soluble receptor are associated with limitations in physical functioning only in women: results from the CARLA cohort. BMC Geriatr. 2019;19(1):299. https://doi.org/10.1186/s12877-019-1323-8. van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med. 2009;7(1):12. https://doi.org/10.1186/1741-7015-7-12. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun. 1998;244(1):45–9. https://doi.org/10.1006/bbrc.1998.8203. Chuah YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm. 2013;2013:403460–15. https://doi.org/10.1155/2013/403460. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R39. https://doi.org/10.1186/ar2645. Perrone A, Giovino A, Benny J, Martinelli F. Advanced glycation end products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects. Oxidative Med Cell Longev. 2020;2020:3818196–18. https://doi.org/10.1155/2020/3818196.